HC Wainwright Reiterates Buy Rating for Aquestive Therapeutics (NASDAQ:AQST)

HC Wainwright reissued their buy rating on shares of Aquestive Therapeutics (NASDAQ:AQST - Free Report) in a report released on Tuesday morning,Benzinga reports. HC Wainwright currently has a $10.00 price objective on the stock.

Several other equities analysts have also commented on the stock. Alliance Global Partners reiterated a "buy" rating on shares of Aquestive Therapeutics in a research note on Friday, March 7th. Raymond James Financial set a $7.00 target price on shares of Aquestive Therapeutics in a research report on Friday, March 7th. Lake Street Capital cut their price target on shares of Aquestive Therapeutics from $10.00 to $8.00 and set a "buy" rating on the stock in a research note on Friday, March 7th. Finally, Oppenheimer began coverage on shares of Aquestive Therapeutics in a research note on Monday, June 2nd. They issued an "outperform" rating and a $7.00 price objective for the company. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Aquestive Therapeutics currently has a consensus rating of "Buy" and an average target price of $10.14.

Aquestive Therapeutics Trading Down 4.4%

Shares of AQST stock traded down $0.15 on Tuesday, reaching $3.25. 1,677,003 shares of the stock were exchanged, compared to its average volume of 1,555,006. The company has a market capitalization of $322.82 million, a price-to-earnings ratio of -5.51 and a beta of 1.94. The business's 50 day moving average price is $2.84 and its 200 day moving average price is $3.05. Aquestive Therapeutics has a twelve month low of $2.12 and a twelve month high of $5.80.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last announced its quarterly earnings results on Monday, May 12th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.07). The business had revenue of $8.72 million during the quarter, compared to the consensus estimate of $12.23 million. Equities research analysts forecast that Aquestive Therapeutics will post -0.46 earnings per share for the current year.

Institutional Trading of Aquestive Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Summit Wealth & Retirement Planning Inc. purchased a new position in Aquestive Therapeutics during the 1st quarter worth $29,000. Victory Capital Management Inc. acquired a new stake in shares of Aquestive Therapeutics during the first quarter worth about $31,000. Cambridge Investment Research Advisors Inc. acquired a new stake in shares of Aquestive Therapeutics during the first quarter worth about $33,000. New York State Common Retirement Fund grew its holdings in shares of Aquestive Therapeutics by 713.3% during the fourth quarter. New York State Common Retirement Fund now owns 12,200 shares of the company's stock worth $43,000 after buying an additional 10,700 shares during the last quarter. Finally, Dynamic Technology Lab Private Ltd purchased a new position in shares of Aquestive Therapeutics during the fourth quarter worth about $44,000. Hedge funds and other institutional investors own 32.45% of the company's stock.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.